Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous stromal vascular fraction-enriched fat graft
- Development stage
- Unknown
- Lead developer
- Antria
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Subcutaneous
01
Overview
Autologous Stromal Vascular Fraction (SVF) is a cellular concentrate derived from a patient's own adipose tissue, containing a heterogeneous population of cells including adipose-derived stem cells (ADSCs), endothelial progenitor cells, pericytes, and various immune cells. Developed by Antria for the treatment of facial atrophy, this therapy involves supplementing standard autologous fat grafts with SVF prior to injection. The mechanism of action relies on the regenerative properties of the SVF cells, which enhance the survival and volume retention of the fat graft by promoting rapid neovascularization (angiogenesis), reducing inflammation-mediated cell death, and providing a source of progenitor cells that can differentiate into mature adipocytes. This approach, often termed cell-assisted lipotransfer, aims to provide more predictable and long-lasting aesthetic results compared to conventional fat grafting.
- Brand names
- Adiployx
- Other names
- SVFSVF-enriched fat graftCell-Assisted LipotransferCALautologous stromal vascular fraction
Beyond the preview
Go deeper on autologous stromal vascular fraction-enriched fat graft.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous stromal vascular fraction-enriched fat graft.